论文部分内容阅读
目的:探讨孟鲁司特钠联合阿斯美治疗咳嗽变异型哮喘临床疗效。方法:将2009年1月至2012年1月我科收治的咳嗽变异型哮喘患者60例随机分成对照组和治疗组各30例,分别应用吸入性糖皮质激素、孟鲁司特钠联合阿斯美进行治疗,比较两组治疗2周和12周的临床症状的改善程度复发情况及不良反应发生情况。结果:治疗2周时治疗组咳嗽症状痊愈率和总有效率分别为26.7%和83.3%,均明显高于对照组的6.7%和56.7%,P均<0.05;治疗12周时两组咳嗽症状痊愈率、总有效率、总复发率和不良反应发生率均无显著性差异。结论:孟鲁司特钠联合阿斯美可迅速缓解咳嗽变异型哮喘的咳嗽症状,且不良反应少,复发率低,建议临床推广。
Objective: To investigate the clinical efficacy of montelukate combined with aspirin in the treatment of cough variant asthma. Methods: From January 2009 to January 2012, 60 patients with cough variant asthma admitted to our department were randomly divided into control group and treatment group, 30 patients were treated with inhaled glucocorticoid, montelukast sodium combined with Aspen The United States for treatment, compared two weeks and 12 weeks of treatment to improve the clinical symptoms of relapse and the occurrence of adverse reactions. Results: The cure rate and total effective rate of cough in treatment group were 26.7% and 83.3% respectively at 2 weeks after treatment, which were significantly higher than 6.7% and 56.7% in control group (P <0.05). Cough symptom There was no significant difference in cure rate, total effective rate, total relapse rate and incidence of adverse reactions. Conclusion: Montelukast combined with aspirin can relieve the cough symptoms of cough variant asthma rapidly with few adverse reactions and low recurrence rate, and it is recommended for clinical promotion.